CL2015001304A1 - Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos. - Google Patents

Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.

Info

Publication number
CL2015001304A1
CL2015001304A1 CL2015001304A CL2015001304A CL2015001304A1 CL 2015001304 A1 CL2015001304 A1 CL 2015001304A1 CL 2015001304 A CL2015001304 A CL 2015001304A CL 2015001304 A CL2015001304 A CL 2015001304A CL 2015001304 A1 CL2015001304 A1 CL 2015001304A1
Authority
CL
Chile
Prior art keywords
pyridin
compounds
fluoro
preparation
amine containing
Prior art date
Application number
CL2015001304A
Other languages
English (en)
Inventor
Ulrich Lücking Dr
Niels Böhnke Dr
Arne Scholz Dr
Philip Lienau Dr
Gerhard Siemeister Dr
Ulf Bömer Dr
Dirk Kosemund Dr
Rolf Bohlmann Dr
Ludwig Zorn Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2015001304A1 publication Critical patent/CL2015001304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina y que presentan la fórmula general (I), como se describen y definen en la presente. Métodos para prepararlas. Su uso en el tratamiento y/o la profilaxis de diversos trastornos, particularmente de los trastornos hiperproliferativos, de las enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Compuestos intermediarios útiles para preparar los compuestos de fórmula general (I).
CL2015001304A 2012-11-15 2015-05-14 Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos. CL2015001304A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12192852 2012-11-15

Publications (1)

Publication Number Publication Date
CL2015001304A1 true CL2015001304A1 (es) 2015-07-17

Family

ID=47148672

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001304A CL2015001304A1 (es) 2012-11-15 2015-05-14 Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.

Country Status (43)

Country Link
US (2) US9650340B2 (es)
EP (1) EP2928878B1 (es)
JP (1) JP6263193B2 (es)
KR (1) KR102242871B1 (es)
CN (1) CN105102444B (es)
AP (1) AP3872A (es)
AR (1) AR093505A1 (es)
AU (1) AU2013346939B2 (es)
BR (1) BR112015010707B1 (es)
CA (1) CA2891358C (es)
CL (1) CL2015001304A1 (es)
CR (1) CR20150256A (es)
CU (1) CU20150052A7 (es)
CY (1) CY1118441T1 (es)
DK (1) DK2928878T3 (es)
DO (1) DOP2015000118A (es)
EA (1) EA027226B1 (es)
EC (1) ECSP15019323A (es)
ES (1) ES2612978T3 (es)
HK (1) HK1213255A1 (es)
HR (1) HRP20161547T1 (es)
HU (1) HUE032868T2 (es)
IL (1) IL238322A (es)
JO (1) JO3332B1 (es)
LT (1) LT2928878T (es)
MA (1) MA38090B1 (es)
ME (1) ME02880B (es)
MX (1) MX2015006169A (es)
MY (1) MY170609A (es)
NZ (1) NZ707084A (es)
PE (1) PE20151071A1 (es)
PH (1) PH12015501003A1 (es)
PL (1) PL2928878T3 (es)
PT (1) PT2928878T (es)
RS (1) RS55580B1 (es)
SG (1) SG11201503079PA (es)
SI (1) SI2928878T1 (es)
SV (1) SV2015004979A (es)
TN (1) TN2015000185A1 (es)
TW (1) TWI613193B (es)
UA (1) UA115254C2 (es)
UY (1) UY35141A (es)
WO (1) WO2014076091A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CN104854091B (zh) 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
CN105283453B (zh) 2012-10-18 2018-06-22 拜耳药业股份公司 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
KR102242871B1 (ko) 2012-11-15 2021-04-20 바이엘 파마 악티엔게젤샤프트 술폭시민 기를 함유하는 5-플루오로-n-(피리딘-2-일)피리딘-2-아민 유도체
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
PT2931713T (pt) 2012-12-17 2017-02-22 Parion Sciences Inc Derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por insuficiente hidratação das mucosas
JP6371385B2 (ja) * 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
CU24399B1 (es) 2014-04-11 2019-04-04 Bayer Pharma AG Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos
CN107001341B (zh) 2014-10-16 2020-08-07 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物
WO2016059011A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
WO2017060167A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
JOP20200196A1 (ar) * 2018-02-13 2020-08-13 Bayer Ag استخدام 5-فلورو-4-(4-فلورو-2-مثوكسي فنيل)- n-{4-[(s-مثيل كبريتون ايميدويل) مثيل] بيريدين-2-يل} بيريدين -2-امين لمعالجة ليمفومة الخلايا البائية الكبيرة المنتشرة
WO2021115335A1 (zh) 2019-12-09 2021-06-17 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
JP2023517034A (ja) * 2020-03-06 2023-04-21 バイエル アクチェンゲゼルシャフト Ｃｄｋ１２の阻害を介してがんに作用するイミダゾトリアジン
CN116249701A (zh) * 2020-10-12 2023-06-09 上海海雁医药科技有限公司 取代的二（吡啶-2-基）胺衍生物、其组合物及医药上的用途
CN117015539A (zh) * 2022-03-25 2023-11-07 成都苑东生物制药股份有限公司 一种氨基吡啶类衍生物、其制备方法及用途
WO2024044757A1 (en) * 2022-08-26 2024-02-29 Sanford Burnham Prebys Medical Discovery Institute Aminopyrimidine and aminotriazine derivatives as myc protein modulators
WO2024097179A1 (en) * 2022-11-02 2024-05-10 Vincerx Pharma, Inc. Combination therapies comprising a cdk9 inhibitor for cancer
WO2024112656A1 (en) * 2022-11-21 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2006064251A1 (en) 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
EP2094681A1 (en) 2006-12-22 2009-09-02 Novartis AG Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2137166B1 (en) * 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
WO2008129070A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CN102933561B (zh) 2010-03-22 2016-05-11 利德发现中心有限责任公司 具有药学活性的二取代三嗪衍生物
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012117059A1 (en) * 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted pyridine derivatives
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
CA2848616A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
EP2755948B1 (en) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
US20150259300A1 (en) 2012-10-18 2015-09-17 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CN104854091B (zh) * 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
US9499492B2 (en) 2012-11-15 2016-11-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
KR102242871B1 (ko) 2012-11-15 2021-04-20 바이엘 파마 악티엔게젤샤프트 술폭시민 기를 함유하는 5-플루오로-n-(피리딘-2-일)피리딘-2-아민 유도체
JP6371385B2 (ja) 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物

Also Published As

Publication number Publication date
SG11201503079PA (en) 2015-06-29
AU2013346939A1 (en) 2015-05-14
US9650340B2 (en) 2017-05-16
EP2928878B1 (en) 2016-11-02
US9877954B2 (en) 2018-01-30
IL238322A0 (en) 2015-06-30
UY35141A (es) 2014-06-30
EA027226B1 (ru) 2017-07-31
LT2928878T (lt) 2016-11-25
US20150291528A1 (en) 2015-10-15
WO2014076091A1 (en) 2014-05-22
BR112015010707A2 (pt) 2017-07-11
JO3332B1 (ar) 2019-03-13
EP2928878A1 (en) 2015-10-14
PL2928878T3 (pl) 2017-04-28
CR20150256A (es) 2015-07-01
CA2891358A1 (en) 2014-05-22
AP2015008432A0 (en) 2015-05-31
SV2015004979A (es) 2017-01-30
DK2928878T3 (en) 2016-12-19
MA38090A1 (fr) 2018-02-28
CA2891358C (en) 2021-05-18
CN105102444B (zh) 2017-08-01
BR112015010707A8 (pt) 2019-10-01
PH12015501003B1 (en) 2015-07-27
TN2015000185A1 (en) 2016-10-03
AU2013346939B2 (en) 2017-06-08
PE20151071A1 (es) 2015-08-19
RS55580B1 (sr) 2017-06-30
NZ707084A (en) 2019-09-27
ES2612978T3 (es) 2017-05-19
JP6263193B2 (ja) 2018-01-17
PH12015501003A1 (en) 2015-07-27
TW201420569A (zh) 2014-06-01
BR112015010707B1 (pt) 2022-05-17
HUE032868T2 (en) 2017-11-28
CU20150052A7 (es) 2015-09-29
CN105102444A (zh) 2015-11-25
EA201590890A1 (ru) 2015-11-30
AR093505A1 (es) 2015-06-10
IL238322A (en) 2017-08-31
MA38090B1 (fr) 2018-09-28
MY170609A (en) 2019-08-20
CY1118441T1 (el) 2017-06-28
HRP20161547T1 (hr) 2016-12-30
HK1213255A1 (zh) 2016-06-30
KR20150084968A (ko) 2015-07-22
US20170202815A1 (en) 2017-07-20
TWI613193B (zh) 2018-02-01
MX2015006169A (es) 2015-08-10
KR102242871B1 (ko) 2021-04-20
UA115254C2 (uk) 2017-10-10
PT2928878T (pt) 2017-02-08
AP3872A (en) 2016-10-31
SI2928878T1 (sl) 2016-12-30
JP2015537015A (ja) 2015-12-24
DOP2015000118A (es) 2015-06-15
ME02880B (me) 2018-04-20
ECSP15019323A (es) 2016-01-29

Similar Documents

Publication Publication Date Title
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
ECSP13013040A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
UY35139A (es) 4- (orto) -fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
WO2014060375A3 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
DOP2016000278A (es) Nuevos compuestos macrocíclicos
UY36938A (es) Nuevos compuestos macrocíclicos modificados
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
BR112014015582A8 (pt) compostos antivirais
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório